Back to Browse Journals » International Journal of High Throughput Screening » Volume 2

Drug discovery in Parkinson's disease: update and developments in the use of cellular models

Authors Skibinski G, Finkbeiner S

Published Date June 2011 Volume 2011:2 Pages 15—25

DOI http://dx.doi.org/10.2147/IJHTS.S8681

Published 30 June 2011

Gaia Skibinski, Steven Finkbeiner
Gladstone Institute of Neurological Disease, San Francisco, CA, USA

Abstract: Parkinson's disease is the second most common neurodegenerative disorder and is characterized by the degeneration of dopaminergic neurons within the substantia nigra. Dopamine replacement drugs remain the most effective treatment for Parkinson's disease but only provide temporary symptomatic relief. New therapies are urgently needed, but the search for a disease-modifying treatment and a definitive understanding of the underlying mechanisms of Parkinson's disease has been limited by the lack of physiologically relevant models that recapitulate the disease phenotype. The use of immortalized cell lines as in vitro model systems for drug discovery has met with limited success, because efficacy and safety too often fail to translate successfully in human clinical trials. Drug discoverers are shifting their focus to more physiologically relevant cellular models, including primary neurons and stem cells. The recent discovery of induced pluripotent stem cell technology presents an exciting opportunity to derive human dopaminergic neurons from patients with sporadic and familial forms of Parkinson's disease. We anticipate that these human dopaminergic models will recapitulate key features of the Parkinson's disease phenotype. In parallel, high-content screening platforms, which extract information on multiple cellular features within individual neurons, provide a network-based approach that can resolve temporal and spatial relationships underlying mechanisms of neurodegeneration and drug perturbations. These emerging technologies have the potential to establish highly predictive cellular models that could bring about a desperately needed revolution in Parkinson's disease drug discovery.

Keywords: Parkinson's disease, cellular models, drug delivery
Corrigendum

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Corrigendum

Skibinski G, Finkbeiner S

International Journal of High Throughput Screening 2011, 2:27-28

Published Date: 22 September 2011

Readers of this article also read:

Eldecalcitol for the treatment of osteoporosis

Noguchi Y, Kawate H, Nomura M, Takayanagi R

Clinical Interventions in Aging 2013, 8:1313-1321

Published Date: 27 September 2013

Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization

Milani P, Massacesi A, Ciaccia S, Setaccioli M, Moschini S, Bergamini F

Clinical Ophthalmology 2012, 6:1885-1894

Published Date: 19 November 2012

Transforming nanostructured chitin from crustacean waste into beneficial health products: a must for our society

Morganti P, Morganti GGM, Morganti AAM

Nanotechnology, Science and Applications 2011, 4:123-129

Published Date: 6 December 2011

Pulmonary thromboendarterectomy after treatment with treprostenil in a chronic thromboembolic pulmonary hypertension patient: a case report

Porpodis K, Konoglou M, Zarogoulidis P, Kaimakamis E, Kontakiotis T, Papakosta D, Zervas V, Katsikogiannis N, Courcoutsakis N, Mitrakas A, Touzopoulos P, Karanikas M, Zarogoulidis K, Markopoulou A

International Journal of General Medicine 2011, 4:767-772

Published Date: 8 November 2011

Head and neck cancer in HIV patients and their parents: a Danish cohort study

Engsig FN, Gerstoft J, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Obel N

Clinical Epidemiology 2011, 3:217-227

Published Date: 21 July 2011

Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis

Payne CM, Crowley-Skillicorn C, Bernstein C, Holubec H, Bernstein H

Clinical and Experimental Gastroenterology 2011, 4:75-119

Published Date: 3 May 2011

Corrigendum

Channing J Paller, Emmanuel S Antonarakis

Drug Design, Development and Therapy 2011, 5:183-184

Published Date: 21 March 2011

Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine

Peter Avery, Shaymaa S Mousa, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2009, 2:79-91

Published Date: 13 September 2009

Microphakonit: 700 micron cataract surgery

Amar Agarwal, Rupal H Trivedi, Soosan Jacob, Athiya Agarwal, Sunita Agarwal

Clinical Ophthalmology 2007, 1:323-325

Published Date: 3 December 2007